赛隆药业审计机构辞任，曾因修正业绩收警示函

Group 1 - The company received a resignation letter from its auditor, Crowe Horwath, citing heavy audit tasks for 2025, significant personnel changes, and scheduling conflicts as reasons for their withdrawal from the audit of the company's financial report and internal controls for 2025 [1][2][3] - The company had previously approved the reappointment of Crowe Horwath in September, and now faces uncertainty in hiring a new auditor before the statutory disclosure deadline for the annual report [1][3] - The company was previously warned by the Guangdong Securities Regulatory Bureau due to significant discrepancies between its annual report and earnings forecast, leading to a decline in stock price and resulting in investor losses [1][2][3] Group 2 - The company initially forecasted no losses for 2024 in its earnings announcement on January 22, 2025, but later reported a substantial loss in its formal annual report released on April 25, with revenue of 264 million [1][4] - The Guangdong Securities Regulatory Bureau noted that the company's earnings forecast was significantly inaccurate, failing to predict revenue below 300 million and losses, and did not disclose potential delisting risk warnings within the required timeframe [4] - The discrepancies in the earnings forecast may indicate unexpected operational challenges and highlight deficiencies in the company's internal controls and governance quality [4]